PureTech Health plc (PRTC) announced on April 29 2026 that it will voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and concentrate trading on the London Stock Exchange (LSE). The company will file a Form 25 with the SEC on or about May 11 2026; the delisting will become effective ten days later, with the last day of Nasdaq trading expected around May 20 2026.
The move is intended to streamline the company’s capital‑markets presence and reduce the regulatory and compliance costs associated with a dual listing. PureTech will also file a Form 15F to deregister its securities and terminate its reporting obligations under the U.S. Exchange Act, further simplifying its U.S. regulatory footprint.
CEO Robert Lyne said, "We have determined that concentrating our listing on the London Stock Exchange is the most effective way to support our shareholders and execute our strategy." He added, "This decision reflects where the meaningful trading volume and liquidity in our shares has consistently occurred, whilst maintaining access to both the UK and global investment community. By simplifying our listing structure, we are streamlining overhead, preserving capital, and ensuring that our resources are focused on advancing our differentiated portfolio and delivering long‑term value."
PureTech reported $277.1 million in cash, cash equivalents, and short‑term investments as of December 31 2025, and a net loss of $109.7 million for the year. Management expects an operational runway extending through at least the end of 2028, including planned participation in Founded Entity financings.
The company operates a "hub‑and‑spoke" model that identifies, de‑risks, and advances high‑conviction therapeutic assets through dedicated Founded Entities. Its portfolio includes candidates for idiopathic pulmonary fibrosis (LYT‑100), myeloid malignancies (LYT‑200), and neuropsychiatric disorders, with several programs in pre‑clinical or early clinical stages.
Several Founded Entities—Celea Therapeutics, Gallop Oncology, and Seaport Therapeutics—are advancing specific programs. Seaport Therapeutics filed a registration statement for a proposed IPO on April 13 2026, illustrating the company’s strategy of leveraging external capital to accelerate development.
By consolidating its listing to the LSE, PureTech aims to reduce dual‑listing costs, lower regulatory burdens, and free capital that can be redirected toward its pipeline and Founded Entity investments, positioning the company for long‑term growth while maintaining global investor access.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.